NCT05939180View on ClinicalTrials.gov

VA vs DA for Newly Diagnosed Hig-risk AML

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

October 1, 2025

Study Completion Date

October 1, 2027

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Venetoclax Oral Tablet

VA regimen: azacytidine, 75mg/m2, subcutaneously, on days 1-7; venetoclax, orally, once a day, 100mg, d1; 200mg, d2; 400mg, days 3-28.

DRUG

Daunorubicin

DA regimen: daunorubicin (60mg/m2) on days 1-3, intraveneously injection, and cytarabine (100mg/m2) on days 1-7, intraveneously injection, for 1 cycle.

Trial Locations (2)

215000

RECRUITING

The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou

215006

RECRUITING

Ethical Committee of the First Affliated Hospital of Soochow University, Suzhou

All Listed Sponsors
lead

The First Affiliated Hospital of Soochow University

OTHER